Robert Rosler

机构：Bristol-Myers Squibb (United States)

发表论文 17 篇 · 总被引 636 次 · h-index 3

代表论文

• Interleukin‐29 uses a type 1 interferon‐like program to promote antiviral responses in human hepatocytes† (2006 · Hepatology · 被引 347)
• Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models (2020 · Molecular Cancer Therapeutics · 被引 225)
• A dual-targeting PDGFRβ/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo (2010 · mAbs · 被引 56)
• Abstract 4222: Tucatinib, a selective small molecule HER2 inibitor, is active in HER2 mutant driven tumors (2020 · Cancer Research · 被引 3)
• Applying population mechanistic modelling to find determinants of chimeric antigen receptor T-cells dynamics in month-one lymphoma patients (2024 · Immunotherapy Advances · 被引 2)
• Abstract 295: CASC-578, a novel Chk1 inhibitor, is active as a single agent in solid tumors and displays synergistic anti-tumor activity in combination with Wee1 inhibition (2017 · Cancer Research · 被引 2)